← Back to Search

Virus Therapy

AlloStim for Coronavirus Disease (ALLOPRIME Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Immunovative Therapies, Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Screening 3 weeks
Treatment Varies
Follow Up day 0 to day 28
Awards & highlights


This trial tests a new vaccine that could protect elderly adults from any type of viral infection, including COVID-19.

Eligible Conditions
  • Coronavirus Disease (COVID-19)
  • Respiratory Syncytial Virus Pneumonia
  • Acute Respiratory Distress Syndrome
  • Viral Diseases
  • Flu
  • Pneumonia


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 to day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 to day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects able to suppress viral propagation
Proportion of subjects with positive T-cell response
frequency of vaccine events

Trial Design

1Treatment groups
Experimental Treatment
Group I: VaccinationExperimental Treatment1 Intervention
ID injection AlloStim Days 0, 3/4, 7, 10/11 and 14
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 2

Find a Location


Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Immunovative Therapies, Ltd.Lead Sponsor
13 Previous Clinical Trials
271 Total Patients Enrolled
Mirror Biologics, Inc.UNKNOWN
2 Previous Clinical Trials
174 Total Patients Enrolled
David Fineberg, MDStudy DirectorMirror Biologics, Inc.
2 Previous Clinical Trials
~10 spots leftby Jul 2025